SCHEDULE: BlackRock Reports Pulmonx Stake

BlackRock, Inc. has updated its Schedule 13G filing, reporting beneficial ownership of 765,721 shares of Pulmonx Corp. common stock, representing 1.8% of the class.

Summary

• BlackRock, Inc. has filed an amendment to its Schedule 13G, indicating its beneficial ownership of Pulmonx Corp. common stock.
• The filing states that BlackRock, Inc. beneficially owns 765,721 shares of Pulmonx Corp. common stock.
• This ownership represents 1.8% of the total outstanding shares of the class.
• BlackRock, Inc. has sole voting power and sole dispositive power over these shares.
• The filing clarifies that this Schedule 13G reflects securities owned by certain business units of BlackRock, Inc. and its subsidiaries and affiliates.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of beneficial ownership by a major institutional investor and does not inherently signal positive or negative news about Pulmonx Corp.'s performance.

Positives

• BlackRock, Inc. maintains a significant stake in Pulmonx Corp., indicating continued investor confidence.
• The ownership percentage of 1.8% suggests a stable, non-controlling interest.

Risks

• The filing does not contain specific risk factors related to Pulmonx Corp. itself, as it is a Schedule 13G filing by an institutional investor.
• Potential risks for Pulmonx Corp. would be detailed in their own SEC filings (e.g., 10-K, 10-Q).

Future Outlook

This filing is an update to beneficial ownership and does not contain forward-looking statements or guidance from Pulmonx Corp.

Management Comments

• BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large institutional investors like BlackRock, Inc. when their ownership stake crosses certain thresholds. This filing indicates BlackRock's ongoing investment in the medical device sector, specifically in companies like Pulmonx Corp. focused on respiratory health.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively for stability, but does not directly impact share price without further context.
• Management of Pulmonx Corp.: Awareness of BlackRock's holdings is standard practice.
• Creditors: No direct impact from this ownership disclosure.

Next Steps

• Pulmonx Corp. will continue to operate and file its regular financial and operational reports.
• BlackRock, Inc. will continue to monitor its investment and may adjust its holdings over time.

Key Dates

Keywords

Pulmonx Corp, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing